Analgesic effects of a 5% lidocaine patch after cesarean section: A randomized placebo-controlled double-blind clinical trial

This study aimed to evaluate the analgesic effects of a 5% lidocaine patch in acute postoperative pain after cesarean section. This is a prospective, randomized, double-blind study. After surgery, active and placebo patches were applied in the operating room, and patients were evaluated during their...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical anesthesia 2021-10, Vol.73, p.110328-110328, Article 110328
Hauptverfasser: de Queiroz, Vaniely Kaliny Pinheiro, da Nóbrega Marinho, Alexandre Magno, de Barros, Guilherme Antonio Moreira
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study aimed to evaluate the analgesic effects of a 5% lidocaine patch in acute postoperative pain after cesarean section. This is a prospective, randomized, double-blind study. After surgery, active and placebo patches were applied in the operating room, and patients were evaluated during their stay at the postoperative recovery room and at the hospital ward. Seventy-two women (18 years of age or older and American Society of Anesthesiologists status II) scheduled for cesarean section under spinal anesthesia were enrolled in the study. Patients were randomly assigned to an intervention or placebo group. According to the assigned group, a 5% lidocaine patch or a placebo patch was applied 1 cm above and below the Pfannenstiel incision after the surgery. The primary outcome was the pain score, evaluated using an 11-point numerical verbal scale in the first 36 h postoperatively. Secondary outcomes were the quality of recovery 24 h after surgery, consumption of rescue opioids, and the presence of adverse effects. Sixty-five women completed the study. The pain score was lower in the lidocaine group at 6 h (lidocaine group: 2.16 ± 1.71, placebo group: 3.21 ± 2.25; p = 0.031), 12 h (lidocaine: 1.58 ± 0.81, placebo: 2.24 ± 0.74; p = 0.001), 24 h (lidocaine: 0.74 ± 0.89, placebo: 1.94 ± 1.39; p 
ISSN:0952-8180
1873-4529
DOI:10.1016/j.jclinane.2021.110328